US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
オーストラリア
ASX
Corporate Travel Management Ltd (CTD) 銘柄情報

Corporate Travel Management Ltd (CTD)

16.07

0.00

(0.00%)

終了 6月6日 3:00PM

Corporate Travel Management Ltd (CTD) 銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

16.07

( - )

買値

16.07

売値

16.07

出来高

0.00

0.00 日の範囲 0.00

11.50 52 週間の範囲 17.01

時価総額

前日終値

16.07

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

AUD 93,277

発行済株式数

138,910,491

配当利回り

0.22 (1.37%)

PER

36.55

1 株当たり利益 (EPS)

0.44

歳入

688.49M

純利益

63.5M

Corporate Travel Management Limited, a travel management solutions company, manages the procurement and delivery of travel services in Australia and New Zealand, North America, Asia, and Europe. . The company provides corporate travels, meetings and event travel management, resources travel, sports ... Corporate Travel Management Limited, a travel management solutions company, manages the procurement and delivery of travel services in Australia and New Zealand, North America, Asia, and Europe. . The company provides corporate travels, meetings and event travel management, resources travel, sports travel, leisure travel, loyalty travel, and wholesale travel services, as well as accommodation agency services. Corporate Travel Management Limited was founded in 1994 and is based in Brisbane, Australia. 詳細を表示

セクター

Consumer Discretionary

業界

Hotels, Lodging & Leisure

ウェブサイト

au.travelctm.com

本社

Brisbane, Australia

設立

1994

Corporate Travel Management Ltd is listed in the Consumer Discretionary sector of the オーストラリア証券取引所 with ticker CTD. The last closing price for Corporate Travel Managem... was AUD16.07. Over the last year, Corporate Travel Managem... shares have traded in a share price range of AUD 11.50 to AUD 17.01.

Corporate Travel Managem... currently has 138,910,491 shares in issue. The market capitalisation of Corporate Travel Managem... is AUD2.23 billion. Corporate Travel Managem... has a price to earnings ratio (PE ratio) of 36.55.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	4.07	33.9166666667	12	16	12	600	16	DE
26	4.06	33.8051623647	12.01	16.51	12	12367	16.50175202	DE
52	2.27	16.4492753623	13.8	17.01	11.5	450981	14.80890846	DE
156	-5.01	-23.7666034156	21.08	21.49	10.8	591147	15.07526318	DE
260	-5.8	-26.520347508	21.87	26.34	10.8	533332	17.13837417	DE

CTD - Frequently Asked Questions (FAQ)

What is the current Corporate Travel Management Ltd share price?

The current share price of Corporate Travel Management Ltd is AUD 16.07

How many Corporate Travel Management Ltd shares are in issue?

Corporate Travel Management Ltd has 138,910,491 shares in issue

What is the market cap of Corporate Travel Management Ltd?

The market capitalisation of Corporate Travel Management Ltd is AUD 2.23B

What is the 1 year trading range for Corporate Travel Management Ltd share price?

Corporate Travel Management Ltd has traded in the range of AUD 11.50 to AUD 17.01 during the past year

What is the PE ratio of Corporate Travel Management Ltd?

The price to earnings ratio of Corporate Travel Management Ltd is 36.55

What is the cash to sales ratio of Corporate Travel Management Ltd?

The cash to sales ratio of Corporate Travel Management Ltd is 3.24

What is the registered address of Corporate Travel Management Ltd?

The registered address for Corporate Travel Management Ltd is 180 Ann Street, Brisbane, Queensland, 4000

What is the Corporate Travel Management Ltd website address?

The website address for Corporate Travel Management Ltd is au.travelctm.com

Which industry sector does Corporate Travel Management Ltd operate in?

Corporate Travel Management Ltd operates in the Hotels, Lodging & Leisure sector

US Market News

US Market News 6分前

Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA BerobenatideJune 6, 2026 9:00 AM
Business Wire Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in

Investor082

Investor082 6分前

They are all a bunch of BS artists! They have trapped many naive retail families over the years by providing false hope and expectations.

Investor082

Investor082 8分前

See you in 2028 then! LP is likely to abandon Eden before that at some point than secure a commercial certification in 2028.

Keep a ton of dry powder. Looking forward to you bragging about averaging down in the coming weeks and months, LOL! ;)

Investor082

Investor082 11分前

In that case, forget about 2026 and 2027. Likely 2028 as well. C lab and Eden won’t certified for commercial production until 2028 at the earliest. Its more likely they will abandon Eden than secure commercial certification even in 2028. Have fun with the endless dilution in pennies! ;)

WhiteOwl

WhiteOwl 12分前

Am I missing something or does that Video say everything is experimental or just theory? I was under the impression they had perfected a workable unit? Just saying.

THE OLD OWL 🦉🦉🦉

hardlesson

hardlesson 15分前

You're one of the hardest working guys on ihub. Banging out the charts on a Saturday morning. Thanks always, and have a good weekend. :)

Investor082

Investor082 15分前

LP will be back there again in a couple years still pleading for a change (pathway act) so she can submit regulatory application to FDA in 2030, LOL!

Meanwhile outstanding shares ballooned to 5B+, LOL! ;)

WhiteOwl

WhiteOwl 15分前

Am I missing something or does that Video say everything is experimental or just theory? I was under the impression they had perfected a workable unit? Just saying.

THE OLD OWL 🦉🦉🦉

glenn1919

glenn1919 19分前

BCDA......BMGL.......BGMS......ACCL......CMND.........CGTL...........https://stockcharts.com/sc3/ui/?s=CMND&p=w&yr=1&mn=3&dy=0&id=p96837884856

Investor082

Investor082 19分前

No excuses when LP disappoints on this, OK?

I will check in on this message whenever there is a decision, LOL! ;)

WhenLambo

WhenLambo 19分前

FIFA is already on public record marketing them, what could be bigger than that? They’ll continue to put VuMe out there next week

train21

train21 21分前

DRIVEN IS BACK
so I guess we going to see 5 cents again ? well are we ?

Investor082

Investor082 22分前

Don't let LP and her toxic financiers screw you year after year, LOL! ;)

Instead invest in well known AI and tech stocks run by solid management crew.

glenn1919

glenn1919 23分前

STAK......SPHL.....SMTK......SAOR.....SNBR.......SCAG.....SPPL..................................https://stockcharts.com/sc3/ui/?s=SCAG&p=w&yr=1&mn=3&dy=0&id=p96837884856

jackinthegreen

jackinthegreen 23分前

Exactly - another round of press and hype can drive the price up a bit, but without substantial new contracts and revenue outside the consumer electronics space, it will only be a temporary bump. We’ve been here before - buying on the rumor is great, but what we need is actual profitability.

train21

train21 24分前

BOTH CEOs BLOCKED ME ON X
I MUST HAVE HIT THE NAIL ON THE HEAD
ANY CEO THAT BLOCKS QUESTIONS OF THEIR DECISIONS IS HIDING SOMETHING BIG AND BAD ???

rodman

rodman 24分前

There appears to be some life left in UEEC based upon the buying and pps increase this week.

cottonmather

cottonmather 25分前

Drey Dossier. The WH Ballroom ain't what it used to be. 17 minutes https://youtu.be/VbJ4ilDvGyc?si=DispyZYqLVQNJyms

USAFpatriot

USAFpatriot 25分前

Annual meeting 8k.

https://investorshub.advfn.com/stock-market/NASDAQ/novocure-NVCR/stock-news/98686681/form-8-k-current-report

train21

train21 26分前

$GTVH YOU ALL NEED TO FILE COMPLAINTS ON THE $OTC WEB SITE AND THE $FINRA WEB SITE
I CAN NOT JUST BE THE ONLY ONE FILING COMPLAINTS HERE ? SOME OF YOU GUYS LOST THOUSANDS $$$$$
CASEY IS A SHARE SELLING SCAMMMER AND MEDIA POSTING LIAR ......... AND THATS ALL THIS STOCK IS

HGiLS

Absolutely — let’s build the full, structured deep-dive you asked for. Below is everything:

• All Eliquis ANDA filers
• Their litigation outcomes
• Each filer’s non-infringement arguments
• Why none succeeded
• Drugs where generics did win using alternative

peafunke

peafunke 28分前

You told ‘who’ so? The fifa concerts are this coming week.

HGiLS

Yes — Eliquis (apixaban) has exactly the kind of ANDA litigation you’re asking about: cases where a generic filer challenged the Orange Book patents and argued non-infringement because their own formulation or manufacturing approach did not fall within the scope of the listed patents.

Teddytropics

Teddytropics 31分前

I will leave it up to you to decide..

I ask myself.. why is this guy so obsessed with Jason Black..?

That he wants to 'to tell on Jason Black' to all..

Where Jason Black isn't involved here anymore except for the CNNA OTC page still listing him..

Corporate Travel Managem...

6.28% Gtd Srs 9 Nts 31/0...

Progress 2005 1

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。